Serum procollagen‐III‐peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia
- 30 April 1989
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 72 (1) , 16-20
- https://doi.org/10.1111/j.1365-2141.1989.tb07644.x
Abstract
In 78 patients with myelofibrosis with myeloid metaplasia (MMM) the serum procollagen III peptide activity (s-PIIIP) had a higher mean value than in 22 normal adult volunteers (22.5 v. 10 ng/ml). Nevertheless, 21.8% of the patients had s-PIIIP within the 95th percentile of the normal control group (16 ng/ml): with respect to those whose concentrations exceeded this limit, patients with normal s-PIIIP levels were younger (55.8 v. 61.2 years), had a higher Hb value (12.3 v. 10.5 g/l), a lower serum ferritin level (106 v. 464 .mu./l) and a higher platelet count (390 v. 216 .times. 109/l). In the overall patient population, s-PIIIP was significantly higher in those with symptoms of active disease (fever, sweating, weight loss) than in subjects with non-active disease (28 v. 16.9 ng/ml). At univariate analysis s-PIIIP correlated (at the 5% level) with increasing WBC, serum ferritin and number of transfusions and with decreasing Hb and platelet count. At multivariate analysis increasing WBC, serum ferritin and age proved to be independently associated with s-PIIIP. No relationship was found between the s-PIIIP level and morphometric grading of bone marrow fibrosis, megakaryocyte number, or lymphoid infiltration. Longitudinal studies showed that s-PIIIP increased with disease progression. The conclusion of the study is that s-PIIIP correlates more with overall disease activity than with the extent of bone marrow fibrosis.This publication has 15 references indexed in Scilit:
- Type III aminoterminal propeptide of procollagen in some haematological malignanciesScandinavian Journal of Haematology, 2009
- A prognostic classification of myelofibrosis with myeloid metaplasiaBritish Journal of Haematology, 1988
- TYPE III PROCOLLAGEN PEPTIDE: A MARKER OF DISEASE ACTIVITY AND PROGNOSIS IN PRIMARY BILIARY CIRRHOSISThe Lancet, 1988
- Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significanceBritish Journal of Haematology, 1986
- Variation in serum Type III procollagen peptide with age in healthy subjects and its comparative value in the assessment of disease activity in children and adults with chronic active hepatitis*European Journal of Clinical Investigation, 1985
- Serum procollagen type III peptide does not reflect hepatic collagen content in alcoholics with inactive cirrhosisJournal of Hepatology, 1985
- Increased serum procollagen III aminoterminal peptide in myelofibrosisAmerican Journal of Hematology, 1983
- Serum Marker of Type III Procollagen in Patients with Idiopathic Hemochromatosis and Its Relationship to Hepatic FibrosisAmerican Journal of Clinical Pathology, 1983
- Idiopathic Myelofibrosis: a Possible Role for Immune‐Complexes in the Pathogenesis of Bone Marrow FibrosisBritish Journal of Haematology, 1981
- Biochemical and Histological Analysis of Bone Marrow Collagen in MyelofibrosisBritish Journal of Haematology, 1979